Pulmonary Medicine

Host: Jacob Sands, MD

Guest: Aaron Lisberg, MD

Brain metastases are a frequent complication of lung cancer, which is why the TROPION-Lung05 trial evaluated the intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced metastatic non-small cell lung cancer (NSCLC). According to the data, Dato-DXd demonstrated intracranial efficacy and equivalent safety between patients who had brain metastases and those who did not. Joining Dr. Jacob Sands to discuss these findings is lead investigator and thoracic medical oncologist Dr. Aaron Lisberg.

Guest: Darvin Scott Smith, MD

For optimal protection, the most prevalent flu strains are assessed every year and included in the vaccine. Here to talk about this process and the recent decision to exclude the B/Yamagata lineage from flu vaccines is Dr. Darvin Scott Smith, Infectious Disease and Geographic Medicine Consultant at San Mateo Medical Center in California.

Host: Charles Turck, PharmD, BCPS, BCCCP

Guest: Christina Madison, BS, PharmD, BCACP, AAHIVP

The World Health Organization and the Vaccines and Related Biologics Products Advisory Committee recently recommended transitioning from quadrivalent to trivalent flu vaccines that exclude the B/Yamagata lineage. Explore the epidemiological data that led to this decision and counseling strategies that can help patients understand this new recommendation with Dr. Charles Turck and Dr. Christina Madison, founder and CEO of the Public Health Pharmacist.

Host: Charles Turck, PharmD, BCPS, BCCCP

Guest: Jill Foster, MD

For optimal protection, the best time for patients to receive a flu shot is between September and October, but some patients may be hesitant. In fact, flu vaccination rates have been declining since the onset of the COVID-19 pandemic according to the CDC. That’s why Dr. Charles Turck speaks with Dr. Jill Foster about how we can help ensure patients receive timely and annual flu vaccinations. Dr. Foster is the Director of the Division of Pediatric Infectious Diseases at the University of Minnesota Medical School in Minneapolis.

Host: Jacob Sands, MD

Guest: Aakesh Desai, MD, MPH

According to research featured at the 2023 ASCO Annual Meeting, novel immune checkpoint targets have the potential to inform drug development and combination strategies to optimize the care of patients with non-small cell lung cancer. Tune in to hear Dr. Jacob Sands explore the key findings with Dr. Aakash Desai, an Assistant Professor of Medicine at the O’Neal Cancer Center at the University of Alabama at Birmingham.

Host: Logan Schneider, MD

The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.

Host: Matthew Davis, MD

Host: Logan Schneider, MD

The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.

Host: Logan Schneider, MD

The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.

Host: Matthew Davis, MD

Host: Alcibiades J. Rodriguez, MD, FAASM

The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.

Host: Matthew Davis, MD

The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.